Showing results (31-40 of 201) with videos related to
Sort By:
Pageof 21
Current Opinion in Pediatrics|December 24, 2013
Toxicity management for patients receiving novel T-cell engaging therapiesDavid M Barrett, David T Teachey, Stephan A GruppBritish Journal of Haematology|April 7, 2009
Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignanciesDavid T Teachey, Stephan A Grupp, Valerie I BrownJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 27, 2023
Future of Treatment of Adolescents and Young Adults With ALL: A Vision for Collaboration and EquityHaley Newman, Stephen P HungerBritish Journal of Haematology|November 26, 2009
Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS)David T Teachey, Alix E Seif, Stephan A GruppFrontiers in Oncology|June 7, 2014
Targeting the PI3K/mTOR Pathway in Pediatric Hematologic MalignanciesSarah K Tasian, David T Teachey, Susan R RheingoldPaediatric Drugs|August 1, 2012
Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignanciesDavid Barrett, Valerie I Brown, Stephan A Grupp, et al.Journal of Pediatric Hematology/Oncology|September 1, 2007
Use of rituximab in conjunction with immunosuppressive chemotherapy as a novel therapy for Epstein Barr virus-associated hemophagocytic lymphohistiocytosisNaomi J Balamuth, Kim E Nichols, Michele Paessler, et al.Cancer Journal (Sudbury, Mass.)|March 27, 2014
Managing cytokine release syndrome associated with novel T cell-engaging therapiesShannon L Maude, David Barrett, David T Teachey, et al.Stem Cells (Dayton, Ohio)|November 13, 2004
Cell division rates of primary human precursor B cells in culture reflect in vivo ratesJonathan Cooperman, Robert Neely, David T Teachey, et al.Blood|May 23, 2015
CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemiaShannon L Maude, David T Teachey, David L Porter, et al.Pageof 21